Baum R P, Lorenz M, Hottenrott C, Albrecht M, Senekowitsch R, Happ J, Hertel A, Spitz J, Hör G
Department of Radiology, University of Frankfurt/Main, Fed. Rep. of Germany.
Int J Biol Markers. 1988 Jul-Sep;3(3):177-84. doi: 10.1177/172460088800300306.
131I labelled F (ab')2 fragments of monoclonal antibodies against CA 19-9 and CEA ("radioimmunococktail" IMACIS 1) were used in a prospective study (n = 60 patients) and in a retrospective study (n = 32 patients) for the detection of colorectal carcinomas (n = 67) and other gastrointestinal CEA/CA 19-9-producing tumors (n = 32). Sensitivity was 82% and specificity 90%. Immunoscintigraphy proved useful and complementary to CT scan and sonography, especially in the diagnosis of pelvic recurrences and intra-abdominal metastases. In addition, monoclonal antibody OC 125 (IMACIS 2) was used for the detection of ovarian carcinomas (n = 10) and other CA 125 producing tumors. Immunoscintigraphy was positive in all patients (n = 18) suggesting that this radioimmunological approach could be of use in the staging, therapeutic control and earlier diagnosis of recurrent epithelial ovarian carcinoma.
用针对CA 19 - 9和癌胚抗原（CEA）的单克隆抗体的131I标记F(ab')2片段（“放射免疫鸡尾酒”IMACIS 1），在一项前瞻性研究（n = 60例患者）和一项回顾性研究（n = 32例患者）中用于检测结直肠癌（n = 67例）和其他产生CEA/CA 19 - 9的胃肠道肿瘤（n = 32例）。敏感性为82%，特异性为90%。免疫闪烁显像被证明是有用的，并且是对CT扫描和超声检查的补充，尤其在盆腔复发和腹腔内转移的诊断中。此外，单克隆抗体OC 125（IMACIS 2）用于检测卵巢癌（n = 10例）和其他产生CA 125的肿瘤。免疫闪烁显像在所有患者（n = 18例）中均为阳性，表明这种放射免疫学方法可用于复发性上皮性卵巢癌的分期、治疗监测和早期诊断。
